Wanbury Ltd Receives No DMF Deficiency Letter from USFDA for ANDAs

Wanbury Limited has announced that it has received a "No DMF deficiency letter" from the US Food and Drug Administration (USFDA) for multiple Abbreviated New Drug Applications (ANDAs). This pertains to the Metformin HCl API source supplied by Wanbury for various formulations. The company also noted its expansion into the South Korean market for another API, for which a Drug Master File (DMF) has been filed. Wanbury reaffirms its commitment to supplying high-quality APIs for human well-being.